ReviewPLoS medicine2019
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
Review in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.Trials · 2021Pooled it
- Guiding principles for pragmatic randomised trials of tuberculosis treatments.The Lancet. Infectious diseases · 2026Review
- Article
- Article
- Article
- Accelerating TB regimen development: introducing FAST-TB.IJTLD open · 2024Article
- Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis.BMJ global health · 2024Article
- Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Frontiers in immunology · 2024Article
- Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.Cell systems · 2021Article
- Advances in clinical trial design: Weaving tomorrow's TB treatments.PLoS medicine · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.